TB-500 is a synthetic peptide derived from thymosin beta-4 (Tβ4), a 43-amino-acid protein found in nearly all mammalian cells. It is studied for its role in actin regulation, and in cell culture and animal models for effects on cell migration, angiogenesis and tissue repair responses. Anyone asking what TB 500 is will find that the name is used inconsistently, sometimes for full-length thymosin beta-4 and sometimes for a short fragment of it. This article explains the distinction, summarises the proposed mechanism and published research, and sets out the verification and storage standards for laboratory material. It is not an approved medicine.
What is TB 500?
TB-500 is a trade name used by research suppliers, not an official nomenclature. In the scientific literature the parent molecule is thymosin beta-4. This is a highly conserved, acidic, 43-residue peptide with an N-terminal acetyl group and a molecular weight of approximately 4963 Da. It was first isolated in the late 1970s and early 1980s by Allan Goldstein and colleagues, who were fractionating extracts of calf thymus (“thymosin fraction 5”). Despite the name, it was later found to be expressed widely outside the thymus, and it is one of the most abundant intracellular peptides in many cell types.
The ambiguity matters for buyers. Much of the material sold as TB-500 is described as the acetylated fragment Ac-LKKTETQ, which corresponds to residues 17 to 23 of thymosin beta-4 and has a molecular weight of roughly 889 Da. This region is the principal actin-binding motif. Other suppliers describe their product as the full-length 43-residue peptide. These are chemically different compounds with different masses, and published findings on full-length thymosin beta-4 do not automatically apply to a fragment.
Regulatory status is straightforward. In the United Kingdom, TB-500 has no marketing authorisation from the MHRA and is not an approved medicine. Thymosin beta-4 and its derivatives are also listed as prohibited substances under the World Anti-Doping Agency code. For laboratory purposes the material is a research chemical, supplied as a lyophilised powder for in-vitro work and ethically approved preclinical studies.
Mechanism of action
The best-characterised function of thymosin beta-4 is the sequestration of globular actin (G-actin). Actin polymerisation drives cell shape, motility and division, and the cell must keep a large pool of unpolymerised monomers available. Thymosin beta-4 binds G-actin in a roughly one-to-one complex and prevents it from joining filaments, which buffers the monomer pool and allows rapid polymerisation when the cell receives a migratory signal. The actin-binding motif centred on the LKKTETQ sequence is central to this interaction.
Beyond actin regulation, several additional activities have been proposed from cell and animal work. Thymosin beta-4 has been reported to promote endothelial cell migration and tube formation in culture, which is the basis for its study in angiogenesis models. It has also been linked to signalling through integrin-linked kinase and the Akt pathway in cardiac cell experiments, and to the mobilisation of epicardial progenitor cells in mouse heart models. Reported effects on inflammatory signalling, including modulation of NF-κB activity, appear in the corneal and dermal wound literature.
Whether the shorter fragment reproduces these activities is a separate question. Some studies on the actin-binding peptide suggest it retains pro-migratory and pro-angiogenic activity in assays, but the evidence is narrower than for the full-length protein. It is also important to note that much of the mechanistic literature concerns intracellular or locally applied thymosin beta-4. How a synthetic peptide behaves in a given assay depends on its form, concentration, cell type and formulation, and the mechanistic picture should be treated as provisional.
What the research shows
The published literature on thymosin beta-4 is broader and more independent than for many research peptides, with work from several groups in different countries. It remains almost entirely preclinical. Four areas are summarised below, without any suggestion that results in cells or animals carry over to people.
The first area is dermal wound healing. Malinda and colleagues reported in the Journal of Investigative Dermatology in 1999 that thymosin beta-4 accelerated wound closure and collagen deposition in rat full-thickness wound models, applied topically or by injection. Observations were made on re-epithelialisation and cell migration, and the work is a frequently cited starting point for the wound-repair literature. Relevant records can be found through a PubMed search on thymosin beta-4 and wound healing. Dose ranges and routes differed between experiments and are not reproduced here, because they were specific to those models.
The second area is cardiac research. In 2004 and 2007, Paul Riley’s group and collaborators published studies in Nature on thymosin beta-4 in mouse myocardial injury models. They reported effects on cardiac cell migration and survival through integrin-linked kinase, and on the mobilisation of epicardial progenitor cells. These papers are well known and have been widely discussed, though they describe mouse models and should be read as mechanistic studies. Records are available through a PubMed search on thymosin beta-4 and cardiac repair.
The third area is ocular surface research. Several studies, notably from Gabriel Sosne and colleagues, examined thymosin beta-4 in corneal epithelial wound models in rodents and in cell culture, reporting effects on migration and on inflammatory markers. This work led to a topical ophthalmic formulation being evaluated in clinical studies by its developer, a regulatory-track programme using pharmaceutical-grade material. Those trials concerned a specific formulation under regulatory oversight and say nothing about research-grade peptides sold for laboratory use.
The fourth area concerns the actin-binding fragment itself. Work published around 2003, including a study in The FASEB Journal, reported that a peptide corresponding to the actin-binding region promoted angiogenesis and wound healing in experimental models. This is the main scientific basis for the use of fragment-based material, although the number of independent studies is smaller than for the full-length protein.
Across all four areas, studies were generally short, used animal groups of modest size and focused on tissue-level outcomes. They are suited to hypothesis generation and assay design. They are not evidence of therapeutic benefit in humans, and no regulator has approved TB-500 for any indication.
Research applications
In cell culture, thymosin beta-4 and its fragments are used to study actin dynamics, cell migration and morphology. Common formats include scratch and transwell migration assays with fibroblasts, keratinocytes and endothelial cells, as well as tube-formation assays on basement membrane matrices. The peptide serves as a test article for comparing migratory responses under defined conditions.
In preclinical animal research it appears in dermal, corneal and cardiac injury models. Such work requires institutional ethical review and, in the United Kingdom, a licence under the Animals (Scientific Procedures) Act 1986 where applicable.
In analytical chemistry, the full-length peptide and its fragment serve as reference materials for method development. The 43-residue molecule, with its acidic character and N-terminal acetylation, is a useful test case for reversed-phase HPLC and for intact-mass analysis by electrospray mass spectrometry, while the heptapeptide fragment suits small-peptide separation work. Laboratories should be explicit about which form they are using, since the two behave very differently chromatographically.
All of these applications are in-vitro or preclinical. Nothing in the literature supports extrapolation to human use.
Purity, storage and handling
Because the name TB-500 covers more than one chemical entity, identity verification is the first quality question, and purity comes second. High-performance liquid chromatography (HPLC) is the standard method for assessing purity, and research-grade peptides are generally expected to reach 98% or higher by this measure. HPLC shows how much of the sample is the main component, but it does not confirm which molecule that is. A credible certificate of analysis therefore includes mass spectrometry. For the full-length peptide the expected mass is approximately 4963 Da, and for the acetylated fragment approximately 889 Da. A certificate that does not state which form was tested, or a mass that matches neither, is a clear warning sign.
The certificate should be batch-specific and carry a batch number matching the vial. A generic or recycled certificate says nothing about the lot received. Researchers should also look for the chromatogram itself rather than a summary figure alone, and for residual trifluoroacetic acid content, water content and, for cell-based work, endotoxin results. Counter-ion and moisture content affect how much peptide a weighed quantity contains, which matters for reproducibility.
Stability is the second consideration. Peptides degrade much faster in solution than as dry powder, and the longer full-length sequence offers more sites for oxidation and hydrolysis than short fragments do. Because of this, batch-level HPLC verification matters more here than with more stable compounds. UK researchers asking what is tb 500 in practical terms should insist on a batch-specific certificate of analysis that names the exact form supplied and on lyophilised storage at -20°C. Those comparing suppliers will also find a Where to buy best peptides UK style shortlist most useful when each candidate publishes this documentation.
Lyophilised powder is typically stable for extended periods at -20°C when kept sealed, dry and protected from light. Short-term storage at 2 to 8°C is commonly tolerated during transit. Vials should reach room temperature before opening, to prevent condensation. Once reconstituted in sterile or bacteriostatic water for laboratory use, solutions are generally kept at 2 to 8°C and used within a short window. Repeated freeze-thaw cycles should be avoided, so single-use aliquots are standard practice. Prolonged light exposure should also be avoided, and amber vials or foil wrapping are common precautions. Standard laboratory personal protective equipment applies, and handling should follow the institution’s chemical risk assessment.
Frequently asked questions
What is TB 500 made of?
TB-500 is a research name for a synthetic peptide based on thymosin beta-4. Suppliers use it for either the full 43-amino-acid protein or the short acetylated fragment Ac-LKKTETQ. The two differ in mass, roughly 4963 Da versus 889 Da, so the certificate of analysis should state which one is supplied.
Is TB 500 the same as thymosin beta-4?
Not necessarily. Thymosin beta-4 is the full-length 43-residue protein, while TB-500 is often sold as a fragment containing its actin-binding region. Published studies mostly describe the full-length protein, so their findings should not be assumed to apply to a fragment without direct experimental evidence.
Is TB 500 approved as a medicine in the UK?
No. TB-500 has no MHRA marketing authorisation and is not an approved medicine in the United Kingdom. It is supplied as a research chemical for laboratory use. Marketing it for human consumption is restricted under medicines legislation, and thymosin beta-4 derivatives are prohibited under World Anti-Doping Agency rules.
How should lyophilised TB 500 be stored in the laboratory?
Lyophilised TB-500 is generally stored sealed at -20°C, protected from light and moisture. Once reconstituted, solutions are usually kept at 2 to 8°C and used within a short period. Single-use aliquots help avoid repeated freeze-thaw cycles. Researchers should always follow the batch documentation and institutional protocols.
This compound is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and nothing in this article should be read as guidance on administration, dosing or therapeutic benefit.